Intravenous immunoglobulin G use in patients with chronic inflammatory demyelinating polyneuropathy: An uncommon cause of drug‐induced discoid lupus erythematosus

Jennings, Tara; Ahmed, Sarah; Aphale, Abhishek; Lee, Jason; Valdés‐Rodríguez, Rodrigo

doi:10.1111/ajd.12998

Cited by 8 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fluorouracil compounds 2 , capecitabine, tegafur, and uracil/tegafur 64 Non-steroidal anti-inflammatory drugs 7 , Anti-TNFα (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab 7 ), Antifungals, intravenous immunoglobulin 65 Other forms of cutaneous LE Lupus tumidus: ustekinumab, bortezomide 58 "Chilblain lupus": infliximab, adalimumab, etarnecept 58 Rowell syndrome: terbinafine 7 LE: lupus erythematosus.…”

Section: Chronic Cutaneous Lementioning

confidence: 99%

Drug-induced lupus erythematosus

Gouveia,

Gonçalo

2023

PJDV

View full text Add to dashboard Cite

Drug-induced lupus erythematosus is an autoimmune disease with unexpected onset after treatment with certain drugs. Clinically, this disease is very similar to idiopathic lupus erythematosus, although its manifestations are typically milder. In addition, the laboratory and histological changes of the induced forms are also not significantly different from the idiopathic condition, sometimes making the diagnosis of the drug-induced form a challenge for clinicians. This entity has been gaining relevance in the clinical setting and the number of drugs associated with it has been increasing, mainly due to the emergence of new biological therapies with a strong causal link with drug-induced lupus, such as tumor necrosis factor-alpha inhibitors. However, there are still no universally accepted diagnostic criteria to identify this disease, and information about its pathophysiology is still somewhat scarce, making it difficult to predict the most likely culprit drugs before there are enough reports to establish a strong link. In addition, although some risk factors have shown susceptibility for certain individuals, they are not yet fully understood. Given the possibility of disease reversal by the withdrawal of the offending drug, it is extremely important to be aware of the possible implication of a drug in the pathogenesis of this disease, and for clinicians who approach patients with lupus manifestations, particularly cutaneous manifestations, it is mandatory to look for the onset of new drugs used by the patient. This review will systematize the current knowledge about this drug-induced lupus, in terms of pathophysiology, clinical, histopathological, and laboratory manifestations, diagnosis, and treatment, as well as the most commonly implicated drugs.

show abstract

Section: Chronic Cutaneous Lementioning

confidence: 99%

Drug-induced lupus erythematosus

Gouveia,

Gonçalo

2023

PJDV

View full text Add to dashboard Cite

show abstract

“…IAN treatment often includes courses of intravenous immunoglobulin (IVIG) 6 . Cutaneous lupus erythematosus (CLE) has developed in IAN patients receiving IVIG in case reports, suggesting a correlation 7,8 . Adrichem et al.…”

mentioning

confidence: 99%